hongkongen
Markets will mirror vaccination success

Markets will mirror vaccination success

08-01-2021 | Monthly outlook
Vaccination rates acting as the key to ending the Covid-19 crisis are seen determining market success in early 2021.
  • Jeroen Blokland
    Jeroen
    Blokland
    Portfolio Manager
  • Richard Purkiss
    Richard
    Purkiss
    Portfolio Manager

Speed read

  • Optimism as vaccinations begin countered by massive spike in cases
  • Equity markets may start to reflect domestic inoculation figures
  • Risk taken off the table but base case for rising earnings remains

Countries began inoculating their populations in December after the Pfizer/BioNTech vaccine was approved. Other vaccines are now being rolled out across the world, just as a new wave of lockdowns have been brought in to stem a rising tide of Christmas holiday infections.

The success that countries have in their vaccination programs, seen as offering the best way out of the lockdowns and the economic damage they have caused, may become reflected in domestic equity markets, Robeco’s investing and health care experts say.

“Throughout 2020, a key theme for equity investors globally was closely tracking new Covid-19 infections at a country level, which certainly correlated with sentiment shifts in local equity markets,” says Jeroen Blokland, Head of the Multi-Asset team.

“Although investors will no doubt continue to monitor infection rates this year too, we think that vaccination rates will be by far the most important barometer of equity market sentiment in 2021.”

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates
Subscribe

Back to square one

Excitement over the first vaccinations has been tempered with a huge spike in infections that has proved to be worse in places than the initial wave in March 2020. “We’re only a few days into 2021, and yet the prospect of a full return to normal by the autumn already appears to be vanishing over the horizon, unless governments everywhere quickly galvanize public health efforts to vaccinate their populations,” says Richard Purkiss, portfolio manager with the Global Equity team and a qualified medical doctor.

“What’s especially disappointing about this prospect is that we witnessed a ’superhuman’ cooperative effort from medical researchers and pharmaceutical companies to produce not just one but several effective and safe vaccines in quantities large enough to begin to meet the challenge of this pandemic in record time.”

“Yet, we then saw ‘pedestrian’ early vaccination rates by health care agencies in all but a few countries where vaccines have now been approved, suggesting that a return to normal by the end of summer is already looking highly improbable.”

Huge spike in cases

The latest Covid-19 figures are scary. Confirmed infections globally now stand at more than 85 million, and estimates of the likely true infected numbers (including all the unconfirmed or silent infections) are somewhere between 5-10 times greater. That represents around 5-11% of the world population, and presents a major logistical challenge for health authorities, not least as all five currently approved vaccines require two doses, given three weeks apart.

“To be relatively certain of avoiding most of the worst economic impacts of the pandemic by the end of September, the global vaccination rate would need to reach 30 million per day for a vaccine that requires two doses,” says Purkiss.

“Our estimate assumes that herd immunity would begin to kick in at the 70% level of vaccination or infection in the population. This could be relatively optimistic, particularly if either of the recently identified and apparently more transmissible UK or South African variants were to become dominant strains worldwide over 2021.”

The key Covid-19 vaccines and their timelines. Source: Bloomberg Vaccine Tracker, January 2021.

Will more strains beat the vaccines?

Then there is the issue of newer or stronger strains emerging that could prove a challenge for the vaccines’ efficacy. “Even assuming vaccine-resistant strains don’t emerge over the next 12 months, most national strategies will probably still struggle to meet their vaccination targets across the year,” Purkiss warns. “As a consequence, it now seems likely that a significant part of the world at least will still be facing many of the same difficulties and economic restrictions in the first half of 2022.”

“Moreover, given how widely spread this coronavirus now is, it is likely to become endemic, and hence vaccine-resistant strains are likely to emerge at some point in the not so distant future. So, continued close surveillance of this virus will still be required even after this pandemic fades, and the need for updated versions of these newly-approved vaccines is not likely to disappear either, unless we want a repeat of 2020!”

Taking risk off the table

For investors, it means taking a much more cautious approach until there is more clarity, says Blokland, whose team has been taking risk off the table since the severity of the latest outbreak became known.

“As we emphasized in our 2021 Outlook (among other publications), the path to a new normal is likely to be rocky, and hiccups in the distribution of vaccines are to be expected,” Blokland says. “As we received more information on the massive challenge the world is facing to reach herd immunity in recent weeks, we reduced the overall risk exposure of our portfolios late last year.”

“The already formidable task for the vaccine – to build a bridge between the current slowdown and better times later – has become even harder. With equity and corporate bond markets already anticipating better times, rising to new all-time highs in the meantime, the odds of a temporary setback have increased. Hence, we have reduced the weight of these asset classes to neutral.”

Earnings can still recover

However, there is still the prospect of ‘jam tomorrow’ as company earnings recover, backed by continuing stimulus programs while the lockdowns are still in place, he says.

“At this point we do not believe there is enough reason to deviate from our base case scenario – that we continue to believe that massive fiscal and monetary stimulus will allow the global economy to resume its recovery,” Blokland says.

“In this scenario, company earnings are expected to rise by at least 20% this year. Given where equity valuations currently are – high in absolute terms but attractive relative to other asset classes – earnings growth will be the main driver of equity returns, pushing markets higher.”

“However, recent developments regarding both the virus as well as vaccination are hampering visibility on when the recovery will actually resume. This bodes for a more neutral stance in our multi-asset portfolios for now.”

Important information

The contents of this document have not been reviewed by the Securities and Futures Commission ("SFC") in Hong Kong. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This document has been distributed by Robeco Hong Kong Limited (‘Robeco’). Robeco is regulated by the SFC in Hong Kong.
This document has been prepared on a confidential basis solely for the recipient and is for information purposes only. Any reproduction or distribution of this documentation, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accepting this documentation, the recipient agrees to the foregoing
This document is intended to provide the reader with information on Robeco’s specific capabilities, but does not constitute a recommendation to buy or sell certain securities or investment products. Investment decisions should only be based on the relevant prospectus and on thorough financial, fiscal and legal advice. Please refer to the relevant offering documents for details including the risk factors before making any investment decisions.
The contents of this document are based upon sources of information believed to be reliable. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Investment Involves risks. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance.

Logo

Disclaimers

1. General
Please read this information carefully.

This website is prepared and issued by Robeco Hong Kong Limited ("Robeco"), which is a corporation licensed by the Securities and Futures Commission in Hong Kong to engage in Type 1 (dealing in securities); Type 4 (advising in securities) and Type 9 (asset management) regulated activities. The Company does not hold client assets and is subject to the licensing condition that it shall seek the SFC’s prior approval before extending services at retail level. This website has not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.

2. Important risk disclosures
2. Important risk disclosures Robeco Capital Growth Funds (“the Funds”) are distinguished by their respective specific investment policies or any other specific features. Please read carefully for the risks of the Funds:

  • Some Funds are subject to investment, market, equities, liquidity, counterparty, securities lending and foreign currency risk and risk associated with investments in small and/or mid-capped companies.
  • Some Funds are subject to the risks of investing in emerging markets which include political, economic, legal, regulatory, market, settlement, execution, counterparty and currency risks.
  • Some Funds may invest in China A shares directly through the Qualified Foreign Institutional Investor (“QFII”) scheme and / or RMB Qualified Foreign Institutional Investor (“RQFII”) scheme and / or Stock Connect programmes which may entail additional clearing and settlement, regulatory, operational, counterparty and liquidity risk.
  • For distributing share classes, some Funds may pay out dividend distributions out of capital. Where distributions are paid out of capital, this amounts to a return or withdrawal of part of your original investment or capital gains attributable to that and may result in an immediate decrease in the net asset value of shares.
  • Some Funds’ investments maybe concentrated in one region / one country / one sector / around one theme and therefore the value of the Fund may be more volatile and may be subject to concentration risk.
  • The risk exists that the quantitative techniques used by some Funds may not work and the Funds’ value may be adversely affected.
  • In addition to investment, market, liquidity, counterparty, securities lending, (reverse) repurchase agreements and foreign currency risk, some Funds are subject to risk associated with fixed income investments like credit risk, interest rate risk, convertible bonds risk, ABS risk and the risk of investments in non-investment grade or unrated securities and the risk of investments made in non-investment grade sovereign securities.
  • Some Funds can use derivatives extensively. Robeco Global Consumer Trends Equities can use derivatives for hedging and efficient portfolio management. Derivatives exposure may involve higher counterparty, liquidity and valuation risks. In adverse situations, the Funds may suffer significant losses (even a total loss of the Funds’ assets) from its derivative usage.
  • Robeco European High Yield Bonds is subject to Eurozone risk.
  • Investors may suffer substantial losses of their investments in the Funds. Investor should not invest in the Funds solely based on the information provided in this document and should read the offering documents (including potential risks involved) for details.

3. Local legal and sales restrictions
The Website is to be accessed by “professional investors” only (as defined in the Securities and Futures Ordinance (Cap.571) and/or the Securities and Futures (Professional Investors) Rules (Cap.571D) under the laws of Hong Kong). The Website is not directed at any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Website is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this Website. Persons accessing the Website need to be aware that they are responsible themselves for the compliance with all local rules and regulations. By accessing this Website and any of its pages, you acknowledge your agreement with understanding of the following terms of use and legal information. If you do not agree to the terms and conditions below, do not access this Website or any pages thereof.

The information contained in the Website is being provided for information purposes.

Neither information nor any opinion expressed on the Website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. The information contained in the Website does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, most recent annual and semi-annual reports, which can be all be obtained free of charge at www.robeco.com/hk/en and at the Robeco Hong Kong office.

4. Use of the Website
The information is based on certain assumptions, information and conditions applicable at a certain time and may be subject to change at any time without notice. Robeco aims to provide accurate, complete and up-to-date information, obtained from sources of information believed to be reliable. Persons accessing the Website are responsible for their choice and use of the information.

5. Investment performance
No assurance can be given that the investment objective of any investment products will be achieved. No representation or promise as to the performance of any investment products or the return on an investment is made. The value of your investments may fluctuate. The value of the assets of Robeco investment products may also fluctuate as a result of the investment policy and/or the developments on the financial markets. Results obtained in the past are no guarantee for the future. Past performance, projection, or forecast included in this Website should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Fund performance figures are based on the month-end trading prices and are calculated on a total return basis with dividends reinvested. Return figures versus the benchmark show the investment management result before management and/or performance fees; the fund returns are with dividends reinvested and based on net asset values with prices and exchange rates of the valuation moment of the benchmark.
Investments involve risks. Past performance is not a guide to future performance. Potential investors should read the terms and conditions contained in the relevant offering documents and in particular the investment policies and the risk factors before any investment decision is made. Investors should ensure they fully understand the risks associated with the fund and should also consider their own investment objective and risk tolerance level. Investors are reminded that the value and income (if any) from shares of the fund may be volatile and could change substantially within a short period of time, and investors may not get back the amount they have invested in the fund. If in doubt, please seek independent financial and professional advice.

6. Third party websites
This website includes material from third parties or links to websites maintained by third parties some of which is supplied by companies that are not affiliated to Robeco. Following links to any other off-site pages or websites of third parties shall be at the own risk of the person following such link. Robeco has not reviewed any of the websites linked to or referred to by the Website and does not endorse or accept any responsibility for their content nor the products, services or other items offered through them. Robeco shall have no liability for any losses or damages arising from the use of or reliance on the information contained on websites of third parties, including, without limitation, any loss of profit or any other direct or indirect damage. Third party off-site pages or websites are provided for informational purposes only.

7. Limitation of liability
Robeco as well as (possible) other suppliers of information to the Website accept no responsibility for the contents of the Website or the information or recommendations contained herein, which moreover may be changed without notice.
Robeco assumes no responsibility for ensuring, and makes no warranty, that the functioning of the Website will be uninterrupted or error-free. Robeco assumes no responsibility for the consequences of e-mail messages regarding a Robeco (transaction) service, which either cannot be received or sent, are damaged, received or sent incorrectly, or not received or sent on time.
Neither will Robeco be liable for any loss or damage that may result from access to and use of the Website.

8. Intellectual property
All copyrights, patents, intellectual and other property, and licenses regarding the information on the Website are held and obtained by Robeco. These rights will not be passed to persons accessing this information.

9. Privacy
Robeco guarantees that the data of persons accessing the Website will be treated confidentially in accordance with prevailing data protection regulations. Such data will not be made available to third parties without the approval of the persons accessing the Website, unless Robeco is legally obliged to do so. Please find more details in our Privacy and Cookie Policy.

10. Applicable law
The Website shall be governed by and construed in accordance with the laws of Hong Kong. All disputes arising out of or in connection with the Website shall be submitted to the exclusive jurisdiction of the courts of Hong Kong. 

Please click the “I agree” button if you have read and understood this page and agree to the Disclaimers above and the collection and use of your personal data by Robeco, for the purposes for which such data is collected and used as set out in the Privacy and Cookie Policy, including for the purpose of direct marketing of Robeco products or services. Otherwise, please click “I Disagree” to leave the website.

I Disagree